Core Insights - Day One Biopharmaceuticals reported preliminary 2025 net product revenue of $155.4 million, reflecting a 172% year-over-year growth, with 2026 U.S. net product revenue projected to be between $225 million and $250 million [1][6] - The company is set to present its corporate progress and priorities for 2026 at the J.P. Morgan Healthcare Conference on January 12, 2026 [1][6] 2025 OJEMDA Commercial Performance - OJEMDA net product revenue for Q4 2025 was approximately $52.8 million, contributing to the full-year revenue of $155.4 million, marking a 37% quarter-over-quarter growth and a 172% year-over-year growth [6] - The increase in revenue was driven by rising patient demand, with prescription volumes reaching 1,394 in Q4 2025 [6] 2026 Corporate Priorities and Key Milestones - The company aims to achieve 2026 OJEMDA net product revenue guidance, focusing on increasing persistency and driving new patient starts to establish OJEMDA as the standard of care in second-line pediatric low-grade glioma (pLGG) [6] - Plans include global expansion of OJEMDA beyond the U.S. through partnerships [6] - Completion of enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial for first-line pLGG is expected in the first half of 2026, with data readout anticipated in mid-2027 and potential approval in 2028 [6] - The Emi-Le program is set to deliver Phase 1 clinical data by mid-2026, progressing towards registration [6] - Initial data from the Phase 1a clinical trial for DAY301, a PTK7-targeted antibody drug conjugate, is expected in the second half of 2026 [6] Financial Position - As of December 31, 2025, prior to the acquisition of Mersana, Day One had approximately $441.1 million in cash, cash equivalents, and short-term investments [5]

Core Insights - Day One Biopharmaceuticals, Inc. is focused on developing targeted therapies for life-threatening diseases, particularly in pediatric cancer, addressing a significant unmet need in therapeutic development [3][4]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company based in Brisbane, California [4]. - The company aims to redefine cancer drug development for all ages, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3]. Group 2: Upcoming Events - Dr. Jeremy Bender, the CEO of Day One, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. Pacific Time [1]. - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days post-event [2]. Group 3: Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4]. - The company collaborates with leading clinical oncologists, families, and scientists to identify and develop important cancer treatments [4].

Company Overview - Day One Biopharmaceuticals, Inc. is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 4:00 p.m. EST [1] - A live webcast of the discussion will be available on the company's Media & Investors page, with an archived replay accessible for 30 days post-event [2] Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4] - The company collaborates with leading clinical oncologists, families, and scientists to identify and develop important cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, X handle, and LinkedIn page to disseminate news, announcements, and financial performance updates [5]

Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on May 6, 2025, at 4:30 p.m. ET to report financial results and discuss corporate progress for Q1 2025 [1] - The live audio of the webcast will be accessible on the Day One Investors & Media page, with an archived version available for replay for 30 days following the event [2] Pipeline and Collaborations - The company's pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, X handle, and LinkedIn page to disseminate news, announcements, and financial performance updates [5]